04:39 PM EDT, 09/19/2025 (MT Newswires) -- Genfit ( GNFT ) said late Friday that it will discontinue its VS-01 program in Acute-on-Chronic Liver Failure after a serious adverse event in a trial and feedback from its data monitoring committee.

The company plans to shift VS-01 development to Urea Cycle Disorder, highlighting its promise in treating acute hyperammonemic crises in pediatric patients, according to the report.

The decision will cut costs, extend its cash runway beyond 2028, and provide flexibility to advance ACLF programs and pursue new opportunities, the company said.